Keywords: Johnson & Johnson, Janssen Biotech, Pharmacyclics, PCI-32765, Anti-cancer compound

J&J to pay nearly $1 billion for cancer drug candidate

Article | 09 December 2011

Print This

US health care giant Johnson & Johnson (NYSE: JNJ), through its subsidiary Janssen Biotech, has executed an agreement with fellow ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in